SciSparc is a specialty pharmaceutical company focused on developing innovative cannabinoid-based therapies aimed at treating various central nervous system (CNS) disorders. The company has a robust pipeline of drug candidates, with four currently in clinical trials targeting conditions such as Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer’s Disease, and Autism Spectrum Disorder. Their proprietary combination platforms utilize various cannabinoids and N-acylethanolamines, leveraging a unique approach to enhance the efficacy of existing FDA-approved compounds. This strategy allows SciSparc to benefit from the FDA’s 505(b)(2) application process, which can lead to reduced development risks and expedited timelines for bringing new therapies to market.

The company’s research emphasizes the modulation of the endocannabinoid system (ECS), a critical network involved in maintaining homeostasis within the body. By targeting the ECS, SciSparc aims to develop therapies that can effectively address neuroinflammatory and neurodegenerative conditions. Their product offerings include SCI-110, which combines Dronabinol and palmitoylethanolamide (PEA) to enhance cannabinoid receptor stimulation, and SCI-210, which features cannabidiol (CBD) and PEA, currently under development in Israel. Additionally, CannAmide™, a PEA formulation, is already available as a supplement for chronic pain and inflammation. Through these innovative approaches, SciSparc is positioned to create significant advancements in the treatment of CNS disorders.

Israel

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.

Nervous System Diseases

SciSparc

Alzheimer's disease

Sleep Apnea Syndromes

Tourette Syndrome

SCI-110

Small Molecule Pharmaceuticals

SCI-110, our proprietary drug candidate, containing Dronabinol (FDA approved synthetic form of THC), with the endocannabinoid palmitoylethanolamide (PEA).&nbsp;
 
Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events.
This product is being developed under the accelerated regulatory path of 505 (b)(2) application focused on augmenting FDA-approved natural and synthetic cannabinoids to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.
 
This approach qualifies us for access to the&nbsp; FDA’s 505 (b)(2) regulatory strategy, created to facilitate the submission of novel drug candidates that meet specific criteria to the FDA for review. The 505 (b)(2) application provides us with several advantages as compared to a typical New Drug Application, including potential; lower risk and development costs, and a potentially expedited time to market.

Autism spectrum disorders

SCI-210, Our proprietary drug candidate containing cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA.
This product is initially being developed under the regulation of the Israeli Medical Cannabis Agency (IMCA) – the agency that leads the regularization of the medical cannabis field in Israel and is the first of its kind in the world. It is a complex, unique, innovative and original process. Conducting clinical trials and development under the regulation of the HQR ostensibly enables rapid and specific registration processes in a track that is unique to Israel.
The company intends to further develop the product for markets outside Israel as well.&nbsp;Indications currently being investigated for treatment with SCI-210 include 
– Autism Spectrum Disorder (in &nbsp;clinical trials) 
– Status Epilepticus – a form of seizures that are severe and sometimes fatal. This indication is currently investigated in pre-clinical settings.

SciSparc

Company Details